Table 1.
Characteristics of NSCLC patients with de novo brain metastasis in baseline (n=233).
| Characteristic | Whole group, n=233 (100%) | EGFR 19del group, n=76 (32.6%) | EGFR 21L858R group, n=94 (40.4%) | EGFR wild-type group, n=46 (19.7%) | EGFR unknown group, n=17 (7.3%) | P value |
|---|---|---|---|---|---|---|
| Age | 0.413 | |||||
| <65 | 189(81.1) | 63(82.9) | 73(77.7) | 37(80.4) | 16(94.1) | |
| ≥65 | 44(18.9) | 13(17.1) | 21(22.3) | 9(19.6) | 1(5.9) | |
| Gender | 0.971 | |||||
| male | 60(25.8) | 19(25) | 25(26.6) | 11(23.9) | 5(29.4) | |
| female | 173(74.2) | 57(75) | 69(73.4) | 35(76.1) | 12(70.6) | |
| ECOG PS | 0.165 | |||||
| 0-1 | 212(91) | 68(89.5) | 85(90.4) | 44(95.7) | 15(88.2) | |
| 2-3 | 21(9) | 8(10.5) | 9(9.6) | 2(4.3) | 2(11.8) | |
| Smoking | <0.001 | |||||
| No | 161(69.1) | 60(78.9) | 64(68.1) | 21(45.7) | 16(94.1) | |
| Yes | 72(30.9) | 16(21.1) | 30(31.9) | 25(54.3) | 1(5.9) | |
| Histology | <0.001 | |||||
| *Non-adenocarcinoma | 21(9) | 0(0) | 3(3.2) | 18(39.1) | 0(0) | |
| Adenocarcinoma | 212(91) | 76(100) | 91(96.8) | 28(60.9) | 17(100) | |
| #Number of BM | 0.644 | |||||
| Limited | 120(51.5) | 40(52.6) | 44(46.8) | 26(56.5) | 10(58.8) | |
| Diffuse | 113(48.5) | 36(47.4) | 50(53.2) | 20(43.5) | 7(41.2) | |
| Extracranial metastasis | 0.531 | |||||
| No | 99(42.5) | 33(43.4) | 37(39.4) | 19(41.3) | 10(58.8) | |
| Yes | 134(57.5) | 43(56.6) | 57(60.6) | 27(58.7) | 7(41.2) | |
| &Radiotherapy | 0.007 | |||||
| No | 69(31.8) | 27(38) | 30(33.7) | 11(26.2) | 1(6.6) | |
| WBRT | 113(52.1) | 36(50.7) | 50(56.2) | 20(47.6) | 7(46.7) | |
| SRS | 30(13.8) | 6(8.5) | 7(7.9) | 10(23.8) | 7(46.7) | |
| WBRT+SRS | 5(2.3) | 2(2.8) | 2(2.2) | 1(2.4) | 0(0) | |
| EGFR-TKIs | <0.001 | |||||
| No | 46(19.7) | 0(0) | 0(0) | 46(100) | 0(0) | |
| Gefitinib | 46(19.7) | 14(18.4) | 26(27.7) | 0(0) | 6(35.3) | |
| Erlotinib | 36(15.5) | 14(18.4) | 16(17) | 0(0) | 6(35.3) | |
| Icotinib | 105(45.1) | 48(63.2) | 52(55.3) | 0(0) | 5(29.4) | |
| Chemotherapy | 0.453 | |||||
| Non-pemetrexed-based | 162(69.5) | 54(71.1) | 69(73.4) | 29(63) | 10(58.8) | |
| Pemetrexed-based | 71(30.5) | 22(28.9) | 25(26.6) | 17(37) | 7(41.2) | |
*Non-adenocarcinoma included 3 cases with adeno-squamous carcinoma, 11 squamous carcinoma, 7 non-small cell lung cancer with unknown histologic subtype.
#Number of BM included the limited BM (1-3 intercranial lesions) and diffuse BM (>3 intercranial lesions).
&Sixteen patients were not having records of radiotherapy.